Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Envista Holdings Corp (NVST) stock saw a decline, ending the day at $19.17 which represents a decrease of $-0.32 or -1.64% from the prior close of $19.49. The stock opened at $19.42 and touched a low ...

Walgreens Boots Alliance beat analysts' lowered expectations for first-quarter adjusted profit on Friday and indicated that ...

Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Illumina in a report released on Tuesday, ...

Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. Amylyx intends to ...

Align Technology upgraded by Leerink Partners with a $280 price target, citing growth potential, stock buyback plans, and global market expansion.

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...